Sun Pharmaceutical Industries Ltd., the world's fifth-largest specialty generic pharmaceutical company with consolidated sales of $4.5bn last year, said it had been buffeted by currency volatility, supply constraints and “significant” costs from its digestion of Ranbaxy Laboratories Ltd., acquired earlier this year from Japan’s Daiichi Sankyo Co. Ltd.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?